---
id: fluoroquinolones-clinical-uses_180
category: antimicrobials
tags: [fluoroquinolones, ciprofloxacin, levofloxacin, moxifloxacin, clinical-uses]
deck: Infectious Diseases
created: 2025-11-11
modified: 2025-11-11
---

## Fluoroquinolones - Specific Clinical Uses

**Q:** What are the key clinical uses for ciprofloxacin, levofloxacin, and moxifloxacin with organism-specific indications and special situations (anthrax, plague, tularemia)?

**A:**

## CIPROFLOXACIN - SPECIFIC USES

**Mnemonic: "PSEUDO-UTI-ANTHRAX-GI"**

### **1. Pseudomonas aeruginosa (BEST Oral Option):**
- **Urinary tract infections** (70-80% susceptible)
- **Chronic suppressive therapy** (prostatitis, recurrent UTI)
- **Oral step-down** (after IV therapy for serious Pseudomonas infections)

### **2. Urinary Tract Infections:**
- **Complicated UTI/pyelonephritis** (E. coli, Klebsiella, Proteus - BUT 20-30% resistance)
- **Dose:** 500mg PO BID x 7 days (cystitis) OR 1000mg XR PO daily x 7-14 days (pyelonephritis)

### **3. Prostatitis (Excellent Prostatic Penetration):**
- **Chronic bacterial prostatitis** (E. coli, Proteus, Pseudomonas)
- **Dose:** 500mg PO BID x 4-6 weeks (chronic) OR 500mg PO BID x 28 days (NIH guideline)

### **4. Enteric Fever (Typhoid Fever):**
- ***Salmonella typhi*** (alternative to ceftriaxone - BUT increasing resistance in South Asia)
- **Dose:** 500mg PO BID x 7-10 days

### **5. Traveler's Diarrhea:**
- **Campylobacter, Shigella, Salmonella, ETEC** (BUT >50% Campylobacter resistance - avoid empiric)
- **Dose:** 500mg PO single dose OR 500mg PO BID x 1-3 days

### **6. Anthrax (Bacillus anthracis):**
- **Post-exposure prophylaxis** (after bioterrorism exposure)
- **Treatment** (inhalational anthrax - IV cipro + protein synthesis inhibitor)
- **Dose:** 500mg PO BID x 60 days (prophylaxis) OR 400mg IV Q8H (treatment)

### **7. Plague (Yersinia pestis):**
- **Alternative to streptomycin/gentamicin**
- **Dose:** 500-750mg PO BID OR 400mg IV Q8-12H x 10-14 days

### **8. Tularemia (Francisella tularensis):**
- **Alternative to doxycycline**
- **Dose:** 500mg PO BID x 14-21 days

**Key Point:** **Cipro = Pseudomonas, UTI, prostatitis, anthrax, plague, tularemia**

---

## LEVOFLOXACIN - SPECIFIC USES

**Mnemonic: "CAP-SINUSITIS-COPD-UTI"**

### **1. Community-Acquired Pneumonia (CAP):**
- **Coverage:** S. pneumoniae, H. influenzae, M. pneumoniae, C. pneumoniae, Legionella
- **IDSA/ATS Recommendation:** Levofloxacin 750mg (respiratory fluoroquinolone)
- **Dose:** 750mg PO/IV daily x 5 days (high-dose short course)

### **2. Acute Bacterial Sinusitis:**
- **Coverage:** S. pneumoniae, H. influenzae, M. catarrhalis
- **Dose:** 750mg PO daily x 5 days OR 500mg PO daily x 10-14 days

### **3. Acute Exacerbation of COPD (AECB):**
- **Coverage:** H. influenzae, M. catarrhalis, S. pneumoniae
- **Dose:** 750mg PO daily x 5 days OR 500mg PO daily x 7 days

### **4. Complicated UTI/Pyelonephritis:**
- **Coverage:** E. coli, Klebsiella, Proteus (BUT 20-30% resistance)
- **Dose:** 750mg PO/IV daily x 5 days (uncomplicated pyelo) OR 750mg daily x 10-14 days (complicated)

### **5. Skin/Soft Tissue Infections:**
- **Coverage:** MSSA, Streptococcus pyogenes
- **Dose:** 750mg PO/IV daily x 7-14 days

**Key Point:** **Levofloxacin 750mg = respiratory fluoroquinolone** (CAP, sinusitis, COPD exacerbation)

---

## MOXIFLOXACIN - SPECIFIC USES

**Mnemonic: "CAP-ATYPICALS-INTRAABDOMINAL-TB"**

### **1. Community-Acquired Pneumonia (CAP with Atypicals):**
- **Coverage:** S. pneumoniae, H. influenzae, M. pneumoniae, C. pneumoniae, Legionella, ANAEROBES
- **Advantage:** **Covers atypicals + anaerobes** (aspiration pneumonia)
- **Dose:** 400mg PO/IV daily x 7-14 days

### **2. Acute Bacterial Sinusitis (Severe/Recurrent):**
- **Coverage:** S. pneumoniae, H. influenzae, anaerobes
- **Dose:** 400mg PO daily x 10 days

### **3. Intraabdominal Infections (Anaerobic Coverage):**
- **Coverage:** Enterobacterales + **Bacteroides fragilis** (anaerobic gram-negatives)
- **Use:** Part of combination therapy (with metronidazole OR as monotherapy)
- **Dose:** 400mg PO/IV daily x 5-14 days

### **4. Mycobacterium tuberculosis (Drug-Resistant TB):**
- **Use:** Alternative agent in MDR-TB/XDR-TB regimens
- **Group:** **WHO Group B agent** (core second-line agent for fluoroquinolone-susceptible MDR-TB)
- **Dose:** 400mg PO daily (as part of MDR-TB regimen)

**Key Point:** **Moxifloxacin = CAP with atypicals, anaerobic coverage, MDR-TB**

---

## DELAFLOXACIN - SPECIFIC USES

### **1. ABSSSI (MRSA Coverage):**
- **FDA-Approved:** Acute bacterial skin and skin structure infections (ABSSSI)
- **Coverage:** MRSA, MSSA, Streptococcus pyogenes, Enterobacterales, Pseudomonas
- **Advantage:** **Active in acidic abscesses** (pH 5.5-6)
- **Dose:** 300mg IV Q12H x 6 doses → 450mg PO BID x 5-14 days (total)

**Key Point:** **Delafloxacin = MRSA ABSSSI** (FDA-approved, active in acidic abscesses)

---

## ANTHRAX (BIOTERRORISM AGENT)

**Mnemonic: "CIPRO-60-DAYS-PLUS-PROTEIN-INHIBITOR"**

### **Post-Exposure Prophylaxis:**
- **Ciprofloxacin 500mg PO BID x 60 days** (OR doxycycline 100mg PO BID x 60 days)
- **Plus:** Anthrax vaccine (3 doses at 0, 2, 4 weeks)

### **Inhalational Anthrax Treatment:**
- **IV Regimen (Initial):**
  - **Ciprofloxacin 400mg IV Q8H** (OR levofloxacin 750mg IV daily)
  - **PLUS**
  - **Protein synthesis inhibitor:** Linezolid 600mg IV Q12H OR clindamycin 900mg IV Q8H
  - **PLUS** (if meningitis suspected)
  - **Meropenem 2g IV Q8H** (for CNS penetration)
- **Duration:** IV therapy until clinically stable → PO to complete **60 days total**

### **Cutaneous Anthrax:**
- **Ciprofloxacin 500mg PO BID x 7-10 days** (OR doxycycline 100mg PO BID)

**Key Point:** **Anthrax prophylaxis = cipro 60 days** | **Treatment = cipro + protein inhibitor**

---

## PLAGUE (YERSINIA PESTIS)

**Mnemonic: "STREPTO-GENTA-CIPRO-DOXY"**

### **First-Line:**
- **Streptomycin 1g IM BID** (OR gentamicin 5mg/kg IV daily)

### **Alternative (If Aminoglycosides Contraindicated):**
- **Ciprofloxacin 400mg IV Q8-12H** (OR 500-750mg PO BID) x 10-14 days
- **Levofloxacin 750mg IV/PO daily** x 10-14 days
- **Doxycycline 100mg IV/PO BID** x 10-14 days

### **Post-Exposure Prophylaxis:**
- **Ciprofloxacin 500mg PO BID x 7 days** (OR doxycycline 100mg PO BID x 7 days)

**Key Point:** **Plague = streptomycin/gentamicin first-line** | **Cipro/doxy alternatives**

---

## TULAREMIA (FRANCISELLA TULARENSIS)

**Mnemonic: "STREPTO-GENTA-CIPRO-DOXY"**

### **First-Line:**
- **Streptomycin 1g IM BID x 10 days** (OR gentamicin 5mg/kg IV daily x 10 days)

### **Alternative (Oral Step-Down):**
- **Ciprofloxacin 500mg PO BID x 14-21 days**
- **Doxycycline 100mg PO BID x 14-21 days** (BUT higher relapse rate than aminoglycosides)

**Key Point:** **Tularemia = streptomycin/gentamicin first-line** | **Cipro/doxy for step-down**

---

## LEGIONNAIRES' DISEASE

**Mnemonic: "AZITHRO-LEVO-MOXI"**

### **First-Line:**
- **Azithromycin 500mg IV/PO daily x 7-10 days** (OR 1g IV x 1 dose → 500mg PO daily x 7 days)

### **Alternative (Fluoroquinolones):**
- **Levofloxacin 750mg IV/PO daily x 7-10 days** (excellent intracellular penetration)
- **Moxifloxacin 400mg IV/PO daily x 7-10 days**

### **Severe/Immunocompromised:**
- **Combination:** Azithromycin + levofloxacin (synergistic)
- **Duration:** 14-21 days (immunocompromised)

**Key Point:** **Legionella = azithromycin first-line** | **Levofloxacin/moxifloxacin alternatives**

---

**Clinical Pearls:**
- **Cipro = Pseudomonas, UTI, prostatitis, anthrax, plague, tularemia**
- **Levofloxacin 750mg = respiratory fluoroquinolone** (CAP, sinusitis, COPD)
- **Moxifloxacin = CAP with atypicals, anaerobic coverage, MDR-TB**
- **Delafloxacin = MRSA ABSSSI** (active in acidic abscesses)
- **Anthrax prophylaxis = cipro 60 days** | **Treatment = cipro + protein inhibitor**
- **Plague = streptomycin/gentamicin first-line** | **Cipro/doxy alternatives**
- **Tularemia = aminoglycosides first-line** | **Cipro for oral step-down**
- **Legionella = azithromycin first-line** | **Levofloxacin/moxifloxacin alternatives**
- **FDA 2016: Avoid fluoroquinolones for uncomplicated sinusitis, bronchitis, UTI**

**Media:**

**Additional Resources:**
- **Sanford Guide:** Fluoroquinolone dosing
- **CDC:** Bioterrorism agents (anthrax, plague, tularemia)
- **IDSA CAP Guidelines:** Fluoroquinolone use

**Sources:** [Sanford Guide], [CDC Bioterrorism], [IDSA CAP Guidelines]
